Lacerta Bio has returned to cold, windy New York following a solid week in sunny, warm San Francisco. We blogged about last year's JP Morgan Healthcare conference here . For…
Last month, Lacerta Bio celebrated its first full year in existence. In fact, our coming out event was JP Morgan 2011. What have we learned in a year? Probably too…
Happy New Year, everyone! Next week, 2012 kicks off with the madness otherwise knows as JP Morgan, or #JPM12 if you prefer. We blogged about last year's conference here. Last…
As 2011 draws to a close, here are a few thoughts on 2011 and 2012: Uncertainty - If there is one word that captures the mood of the year, it…
This week, our good "acquaintances" from EBD Group launched partnering360. What is it? According to EBD: partnering360™ is an online network of professionals in the life science industry, emerging from…
In our view, there are two basic types of biotech business development-related due diligence. The first is external , where the team gathers and analyzes data about a target company…
In a few weeks, Lacerta Bio will return to DC to participate in the annual convention and celebrate the 25th anniversary of the American Association of Pharmaceutical Scientists (AAPS). AAPS…
Earlier this month, Keith Powell posed an interesting question: The economies of California and the UK are similar, as are the university networks. Why then, does California boast the most…
Some members of the media are ebullient with the news that Merck is "getting into venture capital." However, as In Vivo is reporting, Merck is undertaking two initiatives that are…
Lacerta Bio was fortunate to attend this year's BioPharm America conference in Boston. Here are a few of our comments and observations: Are Specialty Markets the Future? - Moderated by…